•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

The new strategy will be managed by five highly accomplished portfolio managers with extensive experience investing in healthcare and biotech stocks. As a group these managers have generated returns greater than the broad S&P 500 over the last decade.

"US healthcare generally, and the biotech and therapeutics sub-sectors in particular, are among the most dynamic and innovative segments of the US and global economies," noted D. Dixon Boardman, CEO of Optima Asset Management and Vice-Chairman of Forbes Family Trust.

"Investment opportunities abound. The growth of the sector is exceptional, yet valuations are remarkably reasonable for many stocks. Furthermore, our extensive research and due diligence have led us to identify outstanding managers whose knowledge of the sector has enabled them to add significant value," he added.

Boardman continued: "Although several of the managers are closed to new investors, we have obtained capacity with them. We therefore believe that the strategy will be highly attractive for institutions as well as high net worth investors."

"We are very pleased to be working with Dixon and the Optima team on the strategy, which is our first joint project," said Keith Bloomfield, CEO of Forbes Family Trust, an affiliate of Optima Asset Management.

Keith added: "Healthcare is one of the largest sector weightings in the S&P 500, and the development of small and mid-cap companies in the sector has been dramatic. It is also noteworthy that the US Food & Drug Administration approved more new drugs last year than ever before. This is a great time for us and for our clients to capitalize on this opportunity."

Optima Asset Management is an affiliate of Forbes Family Trust, a $6.5b wealth and asset management firm and SEC registered investment adviser.